BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Condition:   Relapsed And-or Refractory Multiple Myeloma and Plasmacytoid Lymphoma Intervention:   Biological: BCMA-CD19 cCAR T cells Sponsors:   iCell Gene Therapeutics;   iCAR Bio, China Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials